List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome - Overview
Polycystic Ovarian Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Ovarian Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
AbbVie Inc
Arkay Therapeutics LLC
BioRestorative Therapies Inc
Cadila Healthcare Ltd
EffRx Pharmaceuticals SA
Evotec SE
KinDex Pharmaceuticals Inc
Polycystic Ovarian Syndrome - Drug Profiles
(celecoxib + metformin hydrochloride + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metformin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize PEDF for Women’s Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ThermoStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Ovarian Syndrome - Dormant Projects
Polycystic Ovarian Syndrome - Discontinued Products
Polycystic Ovarian Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Polycystic Ovarian Syndrome - Pipeline by AbbVie Inc, H1 2020
Polycystic Ovarian Syndrome - Pipeline by Arkay Therapeutics LLC, H1 2020
Polycystic Ovarian Syndrome - Pipeline by BioRestorative Therapies Inc, H1 2020
Polycystic Ovarian Syndrome - Pipeline by Cadila Healthcare Ltd, H1 2020
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals SA, H1 2020
Polycystic Ovarian Syndrome - Pipeline by Evotec SE, H1 2020
Polycystic Ovarian Syndrome - Pipeline by KinDex Pharmaceuticals Inc, H1 2020
Polycystic Ovarian Syndrome - Dormant Projects, H1 2020
Polycystic Ovarian Syndrome - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• AbbVie Inc
• Arkay Therapeutics LLC
• BioRestorative Therapies Inc
• Cadila Healthcare Ltd
• EffRx Pharmaceuticals SA
• Evotec SE
• KinDex Pharmaceuticals Inc